Details of the Drug Combination

General Information of Drug Combination (ID: DCFN3PJ)

Drug Combination Name
Lestaurtinib Lestaurtinib
Indication
Disease Entry Status REF
Psoriasis Phase 2 [1]
Component Drugs Lestaurtinib   DMQ2AIJ Lestaurtinib   DMQ2AIJ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Lestaurtinib
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved (orphan drug) [2]
Myeloid leukaemia 2B33.1 Phase 3 [2]
Psoriasis vulgaris EA90 Phase 2/3 [2]
Lestaurtinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Modulator [3]
------------------------------------------------------------------------------------
Indication(s) of Lestaurtinib
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved (orphan drug) [2]
Myeloid leukaemia 2B33.1 Phase 3 [2]
Psoriasis vulgaris EA90 Phase 2/3 [2]
Lestaurtinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Modulator [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Psoriasis DCYWN5X N. A. Phase 2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00236119) Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5672).
3 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.